The issue of whether to switch patients currently taking biologics to biosimilars has been playing out in Canada over the past week, as mandated switching begins in British Columbia, while a reference product maker fights against a possible similar change in 2 other provinces.
The issue of whether to switch patients currently taking biologics to biosimilars has been playing out in Canada over the past week.
Earlier this year, British Columbia became the first Canadian province to mandate that patients currently taking reference biologics for rheumatology indications and for diabetes must be switched to biosimilars over a 6-month period if they use the publicly funded PharmaCare program.
That switch begins this week.
In British Columbia, patients officially begin switching if they take reference products for diabetes, arthritis, and some skin conditions; the move will switch patients to insulin glargine (Lantus), etanercept (Enbrel), and infliximab (Remicade) instead of the reference product.
To mark the move, insurer Pacific Blue Cross created sponsored content to run on a business website cheering the plan and said it was following the same path.
“Biosimilars have similar effectiveness and safety with the same outcomes as the originator drugs at a fraction of the cost,” said Anar Dossa, director of pharmacy services, Pacific Blue Cross. “In response to the Ministry’s decision and in keeping with our longstanding integration with BC PharmaCare, we immediately recommended to our plan sponsors that employees on originator drugs be transitioned to the biosimilar to maintain BC PharmaCare and Pacific Blue Cross coverage.”
The company cited rising drug costs for its decision. Earlier this year, a report said Canada's use of biosimilars has been low relative to other countries because of a combination of factors, including limited awareness of clinical and scientific evidence supporting their use and strong efforts by brand-name biologic companies to retain market share, the report said. The report said that biosimilars make up less than 7% of the biologic market in 2017 while the Organisation for Economic Co-operation and Development average is more than 30%. Seven of the top 10 prescription drugs in Canada are biologics.
Meanwhile, in Ontario and Alberta, patients are being urged by a biologic drug maker to fight any possible switch. A report published a few days ago said that Ontario will begin considering a biosimilar switching policy before the end of the year; Alberta is planning to unveil a new policy later this year.
Both governments said it was too early to say whether they will copy the BC plan.
However, Janssen, a unit of Johnson & Johnson, is warning patients by mail that their provincial governments are considering forced switching from infliximab.
A spokeswoman for Janssen said that the letters were distributed by a third party that provides administrative services for Janssen’s patient-support program, BioAdvance.
Mandated, nonmedical switching has drawn the ire of patient groups. Crohn’s and Colitis Canada and the Canadian Association of Gastroenterology recently published a joint position paper about the topic.
In addition, Diabetes Canada recently put out a statement that the decision to use a biologic or a biosimilar insulin must be made jointly by patients and providers, even as it said that follow-on insulins may be preferred by some.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.